Gary Altwerger, MD
Assistant Professor of Obstetrics and Gynecology; Head of Gynecologic Oncology Morbidity and Mortality , Obstetrics, Gynecology & Reproductive Sciences; Institutional Review Board Committee Member, Gynecologic Oncology
Research & Publications
Biography
News
Locations
Research Summary
Developing novel minimally invasive surgical techniques in gynecologic oncology
Understanding carboplatin hypersensitivity risk factors, elucidating its cause and determining desensitization efficacy for hypersensitive patients.
Identifying and using novel targets like folic acid receptor for the treatment of biologically aggressive uterine cancer.
Use of medical cannabis for pain and peripheral neuropathy in patients with gynecologic cancer.
Coauthors
Research Interests
Drug Hypersensitivity; DNA Mismatch Repair; Lynch Syndrome II; Hereditary Breast and Ovarian Cancer Syndrome
Selected Publications
- Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repairAltwerger G, Ghazarian M, Glazer P. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair. Seminars In Cancer Biology 2023, 98: 11-18. PMID: 38029867, PMCID: PMC10872265, DOI: 10.1016/j.semcancer.2023.11.007.
- Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyWebster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Molecular Cancer Therapeutics 2018, 17: molcanther.0930.2017. PMID: 29440294, PMCID: PMC5932245, DOI: 10.1158/1535-7163.mct-17-0930.
- Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerAltwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.
- Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective studyAltwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology 2016, 144: 77-82. PMID: 27789084, DOI: 10.1016/j.ygyno.2016.09.027.
- Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancerWhicker M, Black J, Altwerger G, Menderes G, Feinberg J, Ratner E. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. American Journal Of Obstetrics And Gynecology 2017, 217: 395-403. PMID: 28411144, DOI: 10.1016/j.ajog.2017.04.012.
- Management of Borderline Ovarian Tumors Based on Patient and Tumor CharacteristicsBlack JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic And Obstetric Investigation 2015, 81: 169-173. PMID: 26067608, DOI: 10.1159/000431219.
- Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region. Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region. International Journal Of Gynecological Cancer 2024, ijgc-2024-005269. PMID: 38719278, DOI: 10.1136/ijgc-2024-005269.
- Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. International Journal Of Gynecological Cancer 2024, ijgc-2024-005358. PMID: 38724238, DOI: 10.1136/ijgc-2024-005358.
- Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbiditiesAlAshqar A, Ghazarian M, Webster E, Upadhyay A, Azodi M, Schwartz P, Ratner E, Altwerger G. Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities. Gynecologic Oncology Reports 2023, 49: 101240. PMID: 37636496, PMCID: PMC10450407, DOI: 10.1016/j.gore.2023.101240.
- Deep infiltrating endometriosis with mucinous metaplasia of mullerian originArkfeld C, Gelissen J, Upadhyay A, Altwerger G. Deep infiltrating endometriosis with mucinous metaplasia of mullerian origin. Journal Of Endometriosis And Pelvic Pain Disorders 2023, 15: 91-94. DOI: 10.1177/22840265231178332.
- Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene MutationsPan Y, Hood A, Ahmad H, Altwerger G. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals Of Pharmacotherapy 2023, 57: 1162-1171. PMID: 36651235, PMCID: PMC11062080, DOI: 10.1177/10600280221149136.